Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2009-09-22 | John L. Higgins 39 Director President and Chief 2009 Executive Officer of Ligand Pharmaceuticals Incorporated, since January 2007. Chief Financial Officer for Connetics Corporation from 1997 to 2007. Director of Ligand Pharmaceuticals Incorporated and BioCryst Pharmaceuticals, Inc. |
| 2010-09-17 | John L. Higgins 27,000 99,500 126,500 |
| 2011-09-16 | John L. Higgins Age: 41 Role: Director Committees: Audit Committee, Executive Compensation Committee Compensation: $107,500 Excerpt: "Mr. Higgins has served on the Company’s Board since 2009..." and "2011 Director Compensation: John L. Higgins, $107,500 total compensation." |
| 2012-09-14 | John L. Higgins has served on the Company 27s Board since 2009. He graduated Magna Cum Laude with a bachelor 27s degree from Colgate University. Mr. Higgins has been President and Chief Executive Officer of Ligand Pharmaceuticals Incorporated since January 2007 and has been a member of Ligand 27s Board of Directors since March 2007. From 1997 until joining Ligand, Mr. Higgins was with Connetics Corporation, a specialty pharmaceutical company, as its Chief Financial Officer, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics from January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006. Mr. Higgins was previously a member of the executive management team at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. Currently, he is a Director of BioCryst and served as Chairperson of its Audit Committee from January 2011 to March 2012. Before joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins also serves as Chairman of CoMentis, Inc., a biopharmaceutical company, and has served as a director of numerous public and private companies. Among other attributes, skills and qualifications, the Board believes Mr. Higgins is qualified to serve as a Director of the Company due to his combination of biopharmaceutical business, accounting and finance experience as well as his executive management experience, particularly with public companies. |
| 2013-09-20 | John L. Higgins has served on the Company 27s Board since 2009. He graduated Magna Cum Laude with a bachelor 27s degree from Colgate University. Mr. Higgins has been President and Chief Executive Officer of Ligand Pharmaceuticals Incorporated since January 2007 and has been a member of Ligand 27s Board of Directors since March 2007. From 1997 until joining Ligand, Mr. Higgins was with Connetics Corporation, a specialty pharmaceutical company, as its Chief Financial Officer, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics from January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006. Mr. Higgins was previously a member of the executive management team and a director at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. Before joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins also serves as Chairman of CoMentis, Inc., a biopharmaceutical company, and has served as a director of numerous public and private companies. Among other attributes, skills and qualifications, the Board believes Mr. Higgins is qualified to serve as a Director of the Company due to his combination of biopharmaceutical business, accounting and finance experience as well as his executive management experience, particularly with public companies. |
| 2014-09-19 | John L. Higgins has served on the Companys Board since 2009. ... During fiscal 2014, the members of the Audit Committee were Mr. Higgins (Chair) ... John L. Higgins $220,640 total compensation. |
| 2015-09-18 | John L. Higgins, age 45, has served on the Company’s Board since 2009. ... Mr. Higgins has been President and Chief Executive Officer of Ligand Pharmaceuticals, Inc. since January 2007. ... The Board believes Mr. Higgins is qualified to serve as a Director of the Company due to his combination of biopharmaceutical business, accounting and finance experience as well as his executive management experience, particularly with public companies. |
| 2016-09-13 | John L. Higgins, age 46, has served on the Company’s Board since 2009. ... The Board currently has three standing Committees: the Audit Committee, the Executive Compensation Committee and the Nominations and Governance Committee. ... The membership of each standing committee during FY 2016 ... John L. Higgins: Audit (Chair), Executive Compensation. ... Directors who are not employees of the Company were compensated for FY 2016 as follows: John L. Higgins total $262,979. |
| 2017-09-12 | Mr. Higgins has been President and CEO of Ligand Pharmaceuticals... The Board has determined that, for FY 2017, Messrs. Baumgartner and Higgins are “audit committee financial experts”... Director Compensation for FY 2017: John L. Higgins total $272,486. |
| 2018-09-11 | Mr. John Higgins has been President and CEO of Ligand Pharmaceuticals... Board believes Mr. Higgins is qualified... Chair of Audit Committee and member of Executive Compensation Committee. Director Compensation Table shows total $273,385. |
| 2019-09-09 | John L. Higgins Age: 49 Independent Director Since: 2009 Other Public Directorships: Ligand Pharmaceuticals, Inc. Mr. Higgins offers the Board over 20 years of industry experience through his role as Chief Executive Officer of Ligand Pharmaceuticals and leadership roles in other pharmaceutical companies. His role with Ligand has given him vital experience in the application of strategic leadership skills within our industry, as well as extensive public company executive and board experience. Mr. Higgins also brings to the Board deep knowledge in accounting and financial matters. Director Compensation for FY 2019 John L. Higgins Total: $277,427 |
| 2020-09-15 | John L. Higgins Age: 50 Independent Director Since: 2009 Chair of Audit Committee Member of Science & Technology Committee Director Compensation for FY 2020: $298,759 |
| 2022-09-14 | John L. Higgins Age: 52 Director since: 2009 INDEPENDENT ...Committee Membership John L. Higgins ...Board Committees John L. Higgins Audit Committee: Chair ...Director Compensation John L. Higgins Total ($): 300,144 |
| 2023-09-13 | John L. Higgins Age: 53 Director since: 2009 INDEPENDENT Committees: • Audit (chair) • Nominations & Governance Compensation Paid to the Non-Employee Directors John L. Higgins $300,298 |
| 2024-09-12 | John L. Higgins Age: 54 Director since: 2009 INDEPENDENT Committees: Audit (chair) Nominations & Governance ...Mr. Higgins offers the Board over 20 years of industry experience through his role as Chief Executive Officer of Ligand Pharmaceuticals and leadership roles in other pharmaceutical companies. ...Compensation Paid to the Non-Employee Directors John L. Higgins Fees Earned or Paid in Cash: $100,000 Stock Awards: $99,954 Option Awards: $100,010 All Other Compensation: $498 Total: $300,462 |
| Filing Date | Source Excerpt |
|---|---|
| 2014-04-21 | He graduated Magna Cum Laude from Colgate University with an A.B. in economics. |
| 2015-03-13 | He graduated Magna Cum Laude from Colgate University with an A.B. in economics. Ligand also benefits from Mr. Higgins' financial experience in leadership roles at companies within the biopharmaceutical industry. |
| 2016-04-12 | Mr. Higgins served as Chief Financial Officer at Connetics Corporation, a specialty pharmaceutical company, and was a member of the healthcare banking team of Dillon, Read & Co. Inc. |
| 2017-04-14 | He graduated Magna Cum Laude from Colgate University with an A.B. in economics. |
| 2018-04-30 | Mr. Higgins graduated Magna Cum Laude from Colgate University with an A.B. in economics. He has financial transaction experience as an investment banker. |
| 2019-04-24 | Mr. Higgins graduated Magna Cum Laude from Colgate University with an A.B. in economics. |
| 2020-04-24 | Mr. Higgins graduated Magna Cum Laude from Colgate University with an A.B. in economics. |
| 2020-11-12 | John L. Higgins is Chief Executive Officer; no software-related skills or technical background mentioned. |
| 2021-04-23 | Mr. Higgins is Chief Executive Officer with experience in finance and management in biotechnology companies. |
| 2022-04-22 | Mr. Higgins is CEO of Ligand Pharmaceuticals and has experience as CFO and executive in pharmaceutical companies. |
Data sourced from SEC filings. Last updated: 2025-12-07